These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 24640100)
21. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180 [TBL] [Abstract][Full Text] [Related]
22. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Tomonari T; Takeishi S; Taniguchi T; Tanaka T; Tanaka H; Fujimoto S; Kimura T; Okamoto K; Miyamoto H; Muguruma N; Takayama T Oncotarget; 2016 Feb; 7(6):7207-15. PubMed ID: 26769852 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934 [TBL] [Abstract][Full Text] [Related]
24. Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient. Dazert E; Colombi M; Boldanova T; Moes S; Adametz D; Quagliata L; Roth V; Terracciano L; Heim MH; Jenoe P; Hall MN Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1381-6. PubMed ID: 26787912 [TBL] [Abstract][Full Text] [Related]
25. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Niu L; Liu L; Yang S; Ren J; Lai PBS; Chen GG Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):564-570. PubMed ID: 29054475 [TBL] [Abstract][Full Text] [Related]
26. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress. Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511 [TBL] [Abstract][Full Text] [Related]
27. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412 [TBL] [Abstract][Full Text] [Related]
28. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358 [TBL] [Abstract][Full Text] [Related]
29. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326 [TBL] [Abstract][Full Text] [Related]
30. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138 [TBL] [Abstract][Full Text] [Related]
32. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma. Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240 [TBL] [Abstract][Full Text] [Related]
33. Network features suggest new hepatocellular carcinoma treatment strategies. Lavi O; Skinner J; Gottesman MM BMC Syst Biol; 2014 Jul; 8():88. PubMed ID: 25070212 [TBL] [Abstract][Full Text] [Related]
34. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604 [TBL] [Abstract][Full Text] [Related]
35. TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells. Ungerleider N; Han C; Zhang J; Yao L; Wu T Mol Carcinog; 2017 Apr; 56(4):1302-1311. PubMed ID: 27862334 [TBL] [Abstract][Full Text] [Related]
36. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167 [TBL] [Abstract][Full Text] [Related]
37. Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. Nishida N; Kitano M; Sakurai T; Kudo M Dig Dis; 2015 Oct; 33(6):771-9. PubMed ID: 26488287 [TBL] [Abstract][Full Text] [Related]
38. Pathways and targets in hepatocellular carcinoma. Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622 [TBL] [Abstract][Full Text] [Related]
39. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Schmieder R; Puehler F; Neuhaus R; Kissel M; Adjei AA; Miner JN; Mumberg D; Ziegelbauer K; Scholz A Neoplasia; 2013 Oct; 15(10):1161-71. PubMed ID: 24204195 [TBL] [Abstract][Full Text] [Related]
40. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. Chow AK; Ng L; Lam CS; Wong SK; Wan TM; Cheng NS; Yau TC; Poon RT; Pang RW PLoS One; 2013; 8(11):e78675. PubMed ID: 24244338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]